🇺🇸 FDA

Intelligence Platform

Patents

Browse 52 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11124787

ADAMTS13-containing compositions having thrombolytic activity

Takeda Pharmaceutical Company Limited · Granted Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11028392

Compositions and methods for inhibiting expression of the ALAS1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10968452

Polynucleotide agents targeting aminolevulinic acid synthase-1 (ALAS1) and uses thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10953083

Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10766892

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System · Granted Tue Sep 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10738043

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10669320

Mps1 and KNL1 phosphorylation system

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10538765

Organic compositions to treat EPAS1-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10400239

Compositions and methods for inhibiting expression of the ALAS1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10344025

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10125128

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10119143

Compositions and methods for inhibiting expression of the ALAS1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10105414

Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal

Julius-Maximilians-Universitat Wurzburg · Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9951017

S1P3 antagonists

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9868949

Organic compositions to treat EPAS1-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9809588

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System · Granted Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9631193

Compositions and methods for inhibiting expression of the ALAS1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9499588

Flaviviruses expressing the prM, E, and NS1 proteins of other flaviviruses and uses thereo

The Board of Regents of the University of Texas System · Granted Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9133461

Compositions and methods for inhibiting expression of the ALAS1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8859727

Bioactive FUS1 peptides and nanoparticle-polypeptide complexes

The Board of Regents of the University of Texas System · Granted Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8735066

Tumor suppressor designated TS10Q23.3

The Board of Regents of the University of Texas System · Granted Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8338366

Bioactive FUS1 peptides and nanoparticle-polypeptide complexes

The Board of Regents of the University of Texas System · Granted Tue Dec 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8252807

Methods of inhibiting the interaction between S100 and the receptor for advanced glycation

The Board of Regents of the University of Texas System · Granted Tue Aug 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7732576

Tumor suppressor designated TS10Q23.3

The Board of Regents of the University of Texas System · Granted Tue Jun 08 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted